N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms.

Erica Neill,Susan L Rossell,Caitlin Yolland,Denny Meyer,Cherrie Galletly,Anthony Harris,Dan Siskind,Michael Berk,Kiymet Bozaoglu,Frances Dark,Olivia M Dean,Paul S Francis,Dennis Liu,Andrea Phillipou,Jerome Sarris,David J Castle

Schizophrenia bulletin（2022）

引用 3|浏览6

暂无评分

摘要

NAC did not significantly improve schizophrenia symptoms, cognition, or quality of life in treatment-resistant patients taking clozapine. This trial was registered with "Australian and New Zealand Clinical Trials" on the 30 May, 2016 (Registration Number: ACTRN12615001273572).

查看译文

关键词

cognition,depression,mental disorders,mental illness,neuroscience,psychiatry,quality of life

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要